FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104069462> ?p ?o ?g. }

• W2104069462 abstract "Most deaths of infants with chronic lung disease (CLD) are caused by respiratory failure, unremitting pulmonary artery hypertension (PAH) with cor pulmonale, or infection. Although the exact prevalence of PAH in infants with CLD is unknown, infants with CLD and severe PAH have a high mortality rate. Except for oxygen supplementation, no specific interventions have been established as effective in the treatment for PAH in premature infants with CLD. Little has been proven regarding the clinical efficacy of vasodilators and concerns remain regarding adverse effects.To review current evidence for the benefits and harms of hydralazine therapy to infants with persistent hypoxemic respiratory failure.We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE via PubMed and EMBASE, and other clinical trials registries through November 2011 using the standard search strategy of the Cochrane Neonatal Review Group. We searched these databases using a strategy combining a variation of the Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE; sensitivity-maximising version with selected MeSH and free-text terms: hydralazine, vasodilator agent, antihypertensive agent, heart diseases, lung diseases, respiratory tract diseases, infant, and randomised controlled trial.We considered only randomised controlled trials and quasi-randomised trials for inclusion. We included low birth weight (LBW) infants with persistent hypoxemic respiratory failure who were treated with any type of hydralazine therapy.Two review authors independently assessed trial quality according to pre-specified criteria.We found no studies meeting the criteria for inclusion in this review.There was insufficient evidence to determine the safety and efficacy of hydralazine in LBW infants with persistent hypoxemic respiratory failure. Since hydralazine is inexpensive and potentially beneficial, randomised controlled trials are recommended. Such trials are particularly needed in settings where other medications such as sildenafil, inhaled nitric oxide (iNO), or extracorporeal membrane oxygenation (ECMO) are not available." @default.
• W2104069462 created "2016-06-24" @default.
• W2104069462 creator A5000330763 @default.
• W2104069462 creator A5006556220 @default.
• W2104069462 creator A5034877069 @default.
• W2104069462 creator A5039357783 @default.
• W2104069462 creator A5039590333 @default.
• W2104069462 creator A5040371822 @default.
• W2104069462 date "2013-02-28" @default.
• W2104069462 modified "2023-10-14" @default.
• W2104069462 title "Hydralazine in infants with persistent hypoxemic respiratory failure" @default.
• W2104069462 cites W103876118 @default.
• W2104069462 cites W1937226585 @default.
• W2104069462 cites W1964689683 @default.
• W2104069462 cites W1966586806 @default.
• W2104069462 cites W1968053961 @default.
• W2104069462 cites W1969536852 @default.
• W2104069462 cites W1989412064 @default.
• W2104069462 cites W2004119748 @default.
• W2104069462 cites W2007868595 @default.
• W2104069462 cites W2011135087 @default.
• W2104069462 cites W2022354799 @default.
• W2104069462 cites W2026939372 @default.
• W2104069462 cites W2036029066 @default.
• W2104069462 cites W2046544582 @default.
• W2104069462 cites W2057427922 @default.
• W2104069462 cites W2060931019 @default.
• W2104069462 cites W2064357794 @default.
• W2104069462 cites W2079732594 @default.
• W2104069462 cites W2093732996 @default.
• W2104069462 cites W2119332119 @default.
• W2104069462 cites W2124257796 @default.
• W2104069462 cites W2127076562 @default.
• W2104069462 cites W2130576870 @default.
• W2104069462 cites W2153537777 @default.
• W2104069462 cites W2157894499 @default.
• W2104069462 cites W2161441636 @default.
• W2104069462 cites W2171549760 @default.
• W2104069462 cites W2330476740 @default.
• W2104069462 cites W2506246053 @default.
• W2104069462 cites W2908608952 @default.
• W2104069462 cites W37342125 @default.
• W2104069462 cites W4206632929 @default.
• W2104069462 cites W4231765742 @default.
• W2104069462 cites W4240331651 @default.
• W2104069462 cites W4248251600 @default.
• W2104069462 cites W4252256576 @default.
• W2104069462 cites W4361868937 @default.
• W2104069462 doi "https://doi.org/10.1002/14651858.cd009449.pub2" @default.
• W2104069462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6465071" @default.
• W2104069462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23450605" @default.
• W2104069462 hasPublicationYear "2013" @default.
• W2104069462 type Work @default.
• W2104069462 sameAs 2104069462 @default.
• W2104069462 citedByCount "1" @default.
• W2104069462 countsByYear W21040694622014 @default.
• W2104069462 crossrefType "journal-article" @default.
• W2104069462 hasAuthorship W2104069462A5000330763 @default.
• W2104069462 hasAuthorship W2104069462A5006556220 @default.
• W2104069462 hasAuthorship W2104069462A5034877069 @default.
• W2104069462 hasAuthorship W2104069462A5039357783 @default.
• W2104069462 hasAuthorship W2104069462A5039590333 @default.
• W2104069462 hasAuthorship W2104069462A5040371822 @default.
• W2104069462 hasBestOaLocation W21040694622 @default.
• W2104069462 hasConcept C126322002 @default.
• W2104069462 hasConcept C168563851 @default.
• W2104069462 hasConcept C177713679 @default.
• W2104069462 hasConcept C187212893 @default.
• W2104069462 hasConcept C197934379 @default.
• W2104069462 hasConcept C2776478404 @default.
• W2104069462 hasConcept C2780521442 @default.
• W2104069462 hasConcept C2780930700 @default.
• W2104069462 hasConcept C535046627 @default.
• W2104069462 hasConcept C71924100 @default.
• W2104069462 hasConcept C84393581 @default.
• W2104069462 hasConceptScore W2104069462C126322002 @default.
• W2104069462 hasConceptScore W2104069462C168563851 @default.
• W2104069462 hasConceptScore W2104069462C177713679 @default.
• W2104069462 hasConceptScore W2104069462C187212893 @default.
• W2104069462 hasConceptScore W2104069462C197934379 @default.
• W2104069462 hasConceptScore W2104069462C2776478404 @default.
• W2104069462 hasConceptScore W2104069462C2780521442 @default.
• W2104069462 hasConceptScore W2104069462C2780930700 @default.
• W2104069462 hasConceptScore W2104069462C535046627 @default.
• W2104069462 hasConceptScore W2104069462C71924100 @default.
• W2104069462 hasConceptScore W2104069462C84393581 @default.
• W2104069462 hasLocation W21040694621 @default.
• W2104069462 hasLocation W21040694622 @default.
• W2104069462 hasLocation W21040694623 @default.
• W2104069462 hasLocation W21040694624 @default.
• W2104069462 hasOpenAccess W2104069462 @default.
• W2104069462 hasPrimaryLocation W21040694621 @default.
• W2104069462 hasRelatedWork W2006523259 @default.
• W2104069462 hasRelatedWork W2036375531 @default.
• W2104069462 hasRelatedWork W2046069863 @default.
• W2104069462 hasRelatedWork W2110954332 @default.
• W2104069462 hasRelatedWork W2337264823 @default.
• W2104069462 hasRelatedWork W2952206796 @default.
• W2104069462 hasRelatedWork W3158407095 @default.
• W2104069462 hasRelatedWork W3184425712 @default.

• next